UNSPSC 51434816: Rescimetol

This classification denotes an antihypertensive agent with the molecular formula C33H38N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25YF317R6S, chemically known as yohimban-16-carboxylic acid, 18-((3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl)oxy)-11,17-dimethoxy-, methyl ester, (3-beta,16-beta,17-alpha,18-beta,20-alpha)- but generally known as rescimetol, which bears US NIH Compound Identifier 5282209.

UNSPSC 51434816 Rescimetol is a Commodity code covering pharmaceutical products, specifically advanced life support and emergency medications used by fire rescue services and state health systems. State and local governments solicit under this code for sealed emergency medications—epinephrine, labetalol, adenosine, and diltiazem injections and vials—supplied to municipal fire departments and integrated into broader pharmacy benefit programs. Issuing bodies include municipal purchasing departments (fire rescue), state health commissions managing pharmacy benefit initiatives, and multistate cooperative purchasing alliances. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent recent buyers, with Tampa seeking immediate supply of life support medications and Texas exploring direct-to-manufacturer prescription contracting at the RFI stage.

Recent activity spans Florida, Texas, and Minnesota-Oregon cooperative purchasing. The City of Tampa's sealed-bid solicitation (26P00188, due April 8, 2026) seeks 370 units of labetalol, 1,810 units of epinephrine, 330 units of adenosine, and 1,020 units of diltiazem for Tampa Fire Rescue, with estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation includes a 5 percent bid discount for Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with two-year terms and pricing weighted at 75 percent of evaluation criteria; products must be sourced through AmerisourceBergen, Cardinal Health, or Morris & Dickson. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026 response deadline) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement as the state develops pharmacy benefit contracting strategy.